BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 37187470)

  • 1. Effects of second-line anti-tuberculosis drugs on the intestinal microbiota of patients with rifampicin-resistant tuberculosis.
    Wu C; Yi H; Hu Y; Luo D; Tang Z; Wen X; Zhang Y; Tang M; Zhang L; Wu S; Chen M
    Front Cell Infect Microbiol; 2023; 13():1127916. PubMed ID: 37187470
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Microbiome in sputum as a potential biomarker of chronicity in pulmonary resistant to rifampicin-tuberculosis and multidrug-resistant-tuberculosis patients.
    Wiqoyah N; Mertaniasih NM; Artama WT; Matsumoto S
    Int J Mycobacteriol; 2021; 10(3):260-267. PubMed ID: 34494564
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Prevalence and transmission of pyrazinamide-resistant
    Liu BB; Hu PL; Chen ZH; Yi SL; Zhang XP; Tan YH
    Zhonghua Jie He He Hu Xi Za Zhi; 2022 Jul; 45(7):677-685. PubMed ID: 35768376
    [No Abstract]   [Full Text] [Related]  

  • 4. Epidemiological profile of multidrug-resistant and extensively drug-resistant Mycobacterium Tubrculosis among Congolese patients.
    Elion Assiana DO; Abdul JBPA; Linguissi LSG; Epola M; Vouvoungui JC; Mabiala A; Biyogho CM; Ronald Edoa J; Adegbite BR; Adegnika AA; Elton L; Canseco JO; McHugh TD; Ahombo G; Ntoumi F
    Ann Clin Microbiol Antimicrob; 2021 Dec; 20(1):84. PubMed ID: 34920727
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Direct Detection by the Xpert MTB/RIF Assay and Characterization of Multi and Poly Drug-Resistant Tuberculosis in Guinea-Bissau, West Africa.
    Rabna P; Ramos J; Ponce G; Sanca L; Mané M; Armada A; Machado D; Vieira F; Gomes VF; Martins E; Colombatti R; Riccardi F; Perdigão J; Sotero J; Portugal I; Couto I; Atouguia J; Rodrigues A; Viveiros M
    PLoS One; 2015; 10(5):e0127536. PubMed ID: 26017968
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Drug-Resistant Characteristics, Genetic Diversity, and Transmission Dynamics of Rifampicin-Resistant Mycobacterium tuberculosis in Hunan, China, Revealed by Whole-Genome Sequencing.
    He W; Tan Y; Liu C; Wang Y; He P; Song Z; Liu D; Zheng H; Ma A; Zhao B; Ou X; Xia H; Wang S; Zhao Y
    Microbiol Spectr; 2022 Feb; 10(1):e0154321. PubMed ID: 35171016
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Factors contributing to the high prevalence of multidrug-resistance/Rifampicin-resistance in patients with tuberculosis: an epidemiological cross sectional and qualitative study from Khabarovsk krai region of Russia.
    Bykov I; Dyachenko O; Ratmanov P; Liu H; Liang L; Wu Q
    BMC Infect Dis; 2022 Jul; 22(1):612. PubMed ID: 35831812
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Transmission and Drug Resistance Genotype of Multidrug-Resistant or Rifampicin-Resistant Mycobacterium tuberculosis in Chongqing, China.
    Zhao B; Liu C; Fan J; Ma A; He W; Hu Y; Zhao Y
    Microbiol Spectr; 2022 Oct; 10(5):e0240521. PubMed ID: 36214695
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Drug susceptibility patterns of Mycobacterium tuberculosis from adults with multidrug-resistant tuberculosis and implications for a household contact preventive therapy trial.
    Demers AM; Kim S; McCallum S; Eisenach K; Hughes M; Naini L; Mendoza-Ticona A; Pradhan N; Narunsky K; Poongulali S; Badal-Faesen S; Upton C; Smith E; Shah NS; Churchyard G; Gupta A; Hesseling A; Swindells S;
    BMC Infect Dis; 2021 Feb; 21(1):205. PubMed ID: 33627075
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sputum microbiota as a potential diagnostic marker for multidrug-resistant tuberculosis.
    Lin D; Wang X; Li Y; Wang W; Li Y; Yu X; Lin B; Chen Y; Lei C; Zhang X; Zhang X; Huang J; Lin B; Yang W; Zhou J; Zeng J; Liu X
    Int J Med Sci; 2021; 18(9):1935-1945. PubMed ID: 33850462
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Age-stratified anti-tuberculosis drug resistance profiles in South Korea: a multicenter retrospective study.
    Lee EG; Min J; Kang JY; Kim SK; Kim JW; Kim YH; Yoon HK; Lee SH; Kim HW; Kim JS
    BMC Infect Dis; 2020 Jun; 20(1):446. PubMed ID: 32576154
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment outcomes of patients with multidrug-resistant and extensively drug resistant tuberculosis in Hunan Province, China.
    Alene KA; Yi H; Viney K; McBryde ES; Yang K; Bai L; Gray DJ; Clements ACA; Xu Z
    BMC Infect Dis; 2017 Aug; 17(1):573. PubMed ID: 28814276
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evolving rifampicin and isoniazid mono-resistance in a high multidrug-resistant and extensively drug-resistant tuberculosis region: a retrospective data analysis.
    Mvelase NR; Balakrishna Y; Lutchminarain K; Mlisana K
    BMJ Open; 2019 Nov; 9(11):e031663. PubMed ID: 31699736
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Whole-genome sequencing for surveillance of fluoroquinolone resistance in rifampicin-susceptible tuberculosis in a rural district of Shanghai: A 10-year retrospective study.
    Zhang Y; Jiang Y; Yu C; Li J; Shen X; Pan Q; Shen X
    Front Public Health; 2022; 10():990894. PubMed ID: 36187694
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interactions of linezolid and second-line anti-tuberculosis agents against multidrug-resistant Mycobacterium tuberculosis in vitro and in vivo.
    Zhao W; Zheng M; Wang B; Mu X; Li P; Fu L; Liu S; Guo Z
    Int J Infect Dis; 2016 Nov; 52():23-28. PubMed ID: 27613365
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Investigation of Efflux Pump Genes in Resistant Mycobacterium tuberculosis Complex Clinical Isolates Exposed to First Line Antituberculosis Drugs and Verapamil Combination].
    Özgür D; Ersoy L; Ülger M; Tezcan Ülger S; Aslan G
    Mikrobiyol Bul; 2023 Apr; 57(2):207-219. PubMed ID: 37067206
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Multidrug-resistant tuberculosis in Imo State, Southeast, Nigeria.
    E Ahiarakwem II; Ekejindu IM; Akujobi CN; Aghanya IN
    Niger J Clin Pract; 2020 Aug; 23(8):1172-1177. PubMed ID: 32788498
    [TBL] [Abstract][Full Text] [Related]  

  • 18. First-line anti-tuberculosis drug resistance trends of Mycobacterium tuberculosis complex isolates. A tertiary hospital study in Turkey.
    Yazısız H; Hırçın Cenger D; Yazısız V; Kılıç L; Altın S
    Tuberk Toraks; 2019 Jun; 67(2):92-101. PubMed ID: 31414639
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Study on the efficacy and safety of short-term treatment including fluoroquinolones anti-tuberculosis drugs for rifampicin resistant pulmonary tuberculosis].
    Kang WL; Xie YG; Tan WG; Chu NH; Li L; You YH; Yang YZ; Wang XM; Yan XL; Miao ZP; Duanmu HJ
    Zhonghua Liu Xing Bing Xue Za Zhi; 2009 Feb; 30(2):179-83. PubMed ID: 19565883
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The second national anti-tuberculosis drug resistance survey in Tanzania, 2017-2018.
    Mutayoba BK; Ershova J; Lyamuya E; Hoelscher M; Heinrich N; Kilale AM; Range NS; Ngowi BJ; Ntinginya NE; Mfaume SM; Nkiligi E; Doulla B; Lyimo J; Kisonga R; Kingalu A; Lema Y; Kondo Z; Pletschette M
    Trop Med Int Health; 2022 Oct; 27(10):891-901. PubMed ID: 36089572
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.